The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Expression and function of PD‐1 in human γδ T cells that recognize phosphoantigens
Abstract
Programmed cell death‐1 (PD‐1) is an inhibitory receptor and plays an important role in the regulation of αβ T cells. Little is known, however, about the role of PD‐1 in γδ T cells. In this study, we investigated the expression and function of PD‐1 in human γδ T cells. Expression of PD‐1 was rapidly induced in primary γδ T cells following antigenic stimulation, and the PD‐1+γδ T cells produced IL‐2. When PD‐1+γδ T cells were stimulated with Daudi cells with and without programmed cell death ligand‐1 (PD‐L1) expression, the levels of IFN‐γ production and cytotoxicity in response to PD‐L1+Daudi cells were diminished compared to the levels seen in response to PD‐L1−Daudi cells. The attenuated effector functions were reversed by anti‐PD‐L1 mAb. When PD‐1+γδ T cells were challenged by PD‐L1+tumors pretreated with zoledronate (Zol), which induced γδ TCR‐mediated signaling, the resulting reduction in cytokine production was only slight to moderate compared to the reduction seen when PD‐1+γδ T cells were challenged by PD‐L1−tumors. In addition, cytotoxic activity of PD‐1+γδ T cells against Zol‐treated PD‐L1+tumors was comparable to that against Zol‐treated PD‐L1−tumors. These results suggest that TCR triggering may partially overcome the inhibitory effect of PD‐1 in γδ T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Self-citationBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., et al. (2003) · Nature Medicine · doi:10.1038/nm955 · Cited by 689
Self-citation
Cited by
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Silva-Santos, B., Mensurado, S., & Coffelt, S. B. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0153-5 · Cited by 425
Unconventional T Cell Targets for Cancer Immunotherapy
Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P., & Rossjohn, J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.009 · Cited by 314
Cancer immunotherapy with γδ T cells: many paths ahead of us
Kabelitz, D., Serrano, R., Kouakanou, L., Peters, C., & Kalyan, S. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0504-x · Cited by 294
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Z., Bai, Y., Lin, A., Jiang, A., Zhou, C., Cheng, Q., Liu, Z., Chen, X., Zhang, J., & Luo, P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01722-0 · Cited by 138
Five Layers of Receptor Signaling in γδ T-Cell Differentiation and Activation
Ribeiro, S. T., Ribot, J. C., & Silva-Santos, B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00015 · Cited by 116
“Programed death-1 (PD-1) is absent or low expressed on circulating Vγ9Vδ2 T-cells but is rapidly induced upon activation (121).”
Background
Metadata
- Authors
- Iwasaki, M., Tanaka, Y., Kobayashi, H., Murata‐Hirai, K., Miyabe, H., Sugie, T., Toi, M., & Minato, N.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2011-01-11
- Volume
- 41
- Issue
- 2
- Pages
- 345-355
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2009704944
- Cited by
- 158
- References
- 8
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.